Home
About Us
About Us
Board of Directors
Scientific Advisory Board
Management Team
Careers
For Researchers
Paxalisib
EVT801
Collaborating with Kazia
Publications and Presentations
For Partners
Our Current Partners
What We Are Looking For
For Patients
Accessing Kazia Drug Candidates in Clinical Trials
Accessing Kazia Drug Candidates for Compassionate Use
Resources for Patients
For Investors
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
Media Centre
Overview
Video
Coverage
Contact
Contact Us
Subscribe to email alerts
Heading &
Sub-heading can be edited through HQI
Home
>
For Investors
>
ASX Announcements
Press Releases
ASX Announcements
Delisting from ASX
How to convert unlisted shares to ADSs
SEC Filings
Corporate Presentations
Annual Reports
Financial Reports
AGM
Corporate Governance
Shareholder Services
ASX Announcements
Filter by Year:
2023
2022
2021
2020
2019
2018
24-Oct-2023
Kazia announces Clinical Data at ESMO 2023 from EVT801 Study
23-Oct-2023
Change in substantial holding
16-Oct-2023
Change of AGM date
13-Oct-2023
Shareholder communication on the ASX de-listing process
11-Oct-2023
Reinstatement to Official Quotation
11-Oct-2023
Kazia announces intention to voluntarily de-list from ASX
10-Oct-2023
Voluntary Suspension
6-Oct-2023
Trading Halt
5-Oct-2023
Presentations at upcoming scientific meetings
29-Sep-2023
Acceptance of late-breaking abstract of PNOC022 data
Previous
1
2
3
4
5
6
7
8
9
Next
